Stock Movers: IBM, Goldman Sachs, HCA Healthcare (Podcast)

IBM shares fell after preliminary Q2 revenue of $17.2B missed estimates of $17.9B, with infrastructure sales down 7% amid customer spending shifts toward chip/server demand tied to AI-fueled shortages. Goldman Sachs rose as quarterly results hit $7.42B, with equities earnings up 72% year over year and investment banking fees at the highest since 2021. HCA Healthcare dropped after cutting its full-year EPS outlook, citing a ~$400M Q2 pre-tax hit from more patients losing Obamacare coverage.

Analysis

IBM’s miss reads less like a one-off execution issue and more like a capital-allocation warning: enterprise AI budgets are concentrating in the hardware layer first, leaving legacy infrastructure vendors with delayed or displaced spend. That is bearish for IBM’s multiple if investors start treating it as a low-beta beneficiary of AI rather than a direct monetizer; the next 1-3 months matter most as order commentary from peers (servers, networking, chips) will tell us whether this is timing noise or a share-loss trend. The second-order winners are the picks-and-shovels names with actual scarcity power in the buildout, not the systems integrators.

Goldman’s strength is more durable near term because volatility itself is the product. When rates, geopolitics, and AI dispersion keep cross-asset spreads wide, trading and financing activity can stay elevated even if cash equities cool; that supports estimate revisions for GS and peers with stronger equities franchises. The risk is that the market extrapolates one hot quarter into a new normalized earnings base just as realized volatility mean-reverts over the next 1-2 quarters.

HCA’s reset is more structural: a payer-mix shock from exchange churn increases bad debt and compresses margin faster than same-store volume can offset it. The spillover matters for hospitals with heavier ACA/Medicaid exposure, while managed-care names may be less directly exposed than the market assumes because the issue is coverage loss, not utilization strength. The key falsifier over 6-12 months is stabilization in exchange enrollment and a reversal in self-pay admissions; absent that, guidance risk remains to the downside.

Key Decisions for Investors

• Short IBM on rallies over the next 1-3 months; thesis is multiple compression if AI capex continues to bypass IBM’s stack. Falsify if infrastructure revenue re-accelerates or backlog/order commentary turns up next quarter.
• Add GS tactically into any pullback for a 1-2 quarter trade; use a call spread rather than outright stock if you want defined risk. Upside is continued estimate revisions from trading/IB leverage; downside is rapid vol normalization.
• Short HCA or buy HCA put spreads for the next 1-3 months; this is a margin squeeze, not just an EPS timing issue. Stop if exchange enrollment and self-pay metrics improve materially in the next earnings update.
• Pair trade: long AI hardware beneficiaries (NVDA or DELL) / short IBM for 1-3 months to express the view that AI dollars are flowing to the infrastructure layer, not legacy platforms. Watch for a reversal only if IBM shows measurable share gains in enterprise infrastructure spend.